选取2015年10月~2017年2月76例初诊T_2DM患者,随机平分对照组采取二甲双胍,研究组采取二甲双胍+沙格列汀,3个月。结果治疗后FPG及2 h PG研究组较对照组低,(P <0.05);研究组FINS较对照组高,HOMA-IR较对照组低,(P <0.05);胃肠道不...选取2015年10月~2017年2月76例初诊T_2DM患者,随机平分对照组采取二甲双胍,研究组采取二甲双胍+沙格列汀,3个月。结果治疗后FPG及2 h PG研究组较对照组低,(P <0.05);研究组FINS较对照组高,HOMA-IR较对照组低,(P <0.05);胃肠道不良反应研究组18.42%(7/38)与对照组10.53%(4/38)(P> 0.05)。结论联合采用二甲双胍及沙格列汀治疗初诊T2DM效果显著,可有效降低FPG、2 h PG,改善胰岛β细胞分泌功能。展开更多
Background and aims Liver cirrhosis is a complex disease that may result in increased morbidity and mortality following bariatric surgery(BS).This study aimed to explore the outcome of BS in patients with unexpected c...Background and aims Liver cirrhosis is a complex disease that may result in increased morbidity and mortality following bariatric surgery(BS).This study aimed to explore the outcome of BS in patients with unexpected cirrhosis,focusing on postoperative complications and the progression of liver disease.Methods A retrospective study of bariatric patients with cirrhosis from four centers in China between 2016 and 2023 was conducted,with follow-up for one year after BS.The primary outcome was the safety of BS in patients with unexpected cirrhosis,while the secondary outcome was the metabolic efficacy of BS in this group postoperatively.Results A total of 47 patients met the study criteria,including 46 cases of Child-Pugh class A cirrhosis and 1 case of Child-Pugh B.Pathological examination confirmed nodular cirrhosis in 21 patients(44.68%),pseudolobule formation in 1 patient(2.13%),lipedema degeneration with inflammatory cell infiltration in 3 patients(6.38%),and chronic hepatitis in 1 patient(2.13%).The average percentage of total weight loss was 29.73±6.53%at one year postoperatively.During the 30-day postoperative period,the complication rate was 6.38%,which included portal vein thrombosis,gastrointestinal bleeding,and intra-abdominal infection.Moreover,no cases of liver decompensation or mortality were reported during the follow-up period.The remission rates of comorbidities among 41 patients one year after surgery were as follows:dyslipidemia 100%,type 2 diabetes 82.61%,hypertension 84.62%,and obstructive sleep apnea syndrome 85.71%.Conclusions BS can be safely performed in patients with unexpected cirrhosis in the compensated stage of liver disease,with low postoperative morbidity and no mortality observed during one-year follow-up.展开更多
文摘选取2015年10月~2017年2月76例初诊T_2DM患者,随机平分对照组采取二甲双胍,研究组采取二甲双胍+沙格列汀,3个月。结果治疗后FPG及2 h PG研究组较对照组低,(P <0.05);研究组FINS较对照组高,HOMA-IR较对照组低,(P <0.05);胃肠道不良反应研究组18.42%(7/38)与对照组10.53%(4/38)(P> 0.05)。结论联合采用二甲双胍及沙格列汀治疗初诊T2DM效果显著,可有效降低FPG、2 h PG,改善胰岛β细胞分泌功能。
基金Science and Technology Program of Xuzhou(No.KC22231)of China.
文摘Background and aims Liver cirrhosis is a complex disease that may result in increased morbidity and mortality following bariatric surgery(BS).This study aimed to explore the outcome of BS in patients with unexpected cirrhosis,focusing on postoperative complications and the progression of liver disease.Methods A retrospective study of bariatric patients with cirrhosis from four centers in China between 2016 and 2023 was conducted,with follow-up for one year after BS.The primary outcome was the safety of BS in patients with unexpected cirrhosis,while the secondary outcome was the metabolic efficacy of BS in this group postoperatively.Results A total of 47 patients met the study criteria,including 46 cases of Child-Pugh class A cirrhosis and 1 case of Child-Pugh B.Pathological examination confirmed nodular cirrhosis in 21 patients(44.68%),pseudolobule formation in 1 patient(2.13%),lipedema degeneration with inflammatory cell infiltration in 3 patients(6.38%),and chronic hepatitis in 1 patient(2.13%).The average percentage of total weight loss was 29.73±6.53%at one year postoperatively.During the 30-day postoperative period,the complication rate was 6.38%,which included portal vein thrombosis,gastrointestinal bleeding,and intra-abdominal infection.Moreover,no cases of liver decompensation or mortality were reported during the follow-up period.The remission rates of comorbidities among 41 patients one year after surgery were as follows:dyslipidemia 100%,type 2 diabetes 82.61%,hypertension 84.62%,and obstructive sleep apnea syndrome 85.71%.Conclusions BS can be safely performed in patients with unexpected cirrhosis in the compensated stage of liver disease,with low postoperative morbidity and no mortality observed during one-year follow-up.
